ProQR appoints new CFO and CMO to drive clinical-stage growth
Ella Day | April 15, 2025 | Appointment | Research and Development | Corporate, ProQR, appointments, clinical development
ProQR Therapeutics announced two major leadership appointments to support its transition into the clinical development phase of its RNA editing programmes. Dennis Hom (pictured left) joins as chief financial officer (CFO), while Cristina Lopez Lopez (pictured right) takes on the role of chief medical officer (CMO).
The Netherlands- and Massachusetts-based biotech continues to advance its proprietary Axiomer RNA editing platform, which targets single nucleotide changes in RNA to correct mutations and potentially treat a range of diseases. The recent appointments will bolster this.
Hom brings over 25 years of financial and corporate development experience to the role, having most recently served as CFO and head of corporate development at Sagimet Biosciences. He also held key roles at Amgen, Novartis and JP Morgan, and will now oversee ProQR’s corporate finance, investor relations and business development.
Lopez Lopez previously led global neurodegeneration strategy at Johnson & Johnson. Her background includes leadership roles at Roche and Novartis, with expertise in translational R&D and precision medicine. At ProQR, she will lead all clinical, regulatory and translational activities.
These appointments follow the planned departures of CFO Jurriaan Dekkers and chief corporate development officer René Beukema, who played key roles in establishing ProQR’s RNA editing focus. Both will remain with the company during a transitional period.
Chief executive officer Daniel de Boer said the new appointments come at “an important time in our evolution,” adding that Hom and Lopez Lopez bring “deep and complementary leadership capabilities” as the company moves forward.
Ella Day
15/4/25
Related Content
Sanofi axes four major players from its executive committee
Sanofi has announced it will cull its executive committee under plans orchestrated by new Chief …
Dr Richard Torbett is named as the new Chief Executive of the ABPI
The Association of the British Pharmaceutical Industry (ABPI) has appointed Dr Richard Torbett as its …
Insys Therapeutics names current CFO Andrew Long as company’s new CEO
Insys Therapeutics has said Andrew Long will take over from Saeed Motahari as the company’s …
